Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;27(7):1976-1979.
doi: 10.3201/eid2707.210118.

Effects of COVID-19 Vaccination Timing and Risk Prioritization on Mortality Rates, United States

Effects of COVID-19 Vaccination Timing and Risk Prioritization on Mortality Rates, United States

Xutong Wang et al. Emerg Infect Dis. 2021 Jul.

Abstract

During rollout of coronavirus disease vaccination, policymakers have faced critical trade-offs. Using a mathematical model of transmission, we found that timing of vaccination rollout would be expected to have a substantially greater effect on mortality rate than risk-based prioritization and uptake and that prioritizing first doses over second doses may be lifesaving.

Keywords: COVID-19; SARS-CoV-2; Texas; United States; coronavirus disease; epidemiology; mathematical model; mortality; pandemics; respiratory infections; severe acute respiratory syndrome coronavirus 2; vaccines; viruses; zoonoses.

PubMed Disclaimer

Figures

Figure
Figure
Projected COVID-19 deaths and deaths averted in the Austin–Round Rock Metropolitan Statistical Area (Austin, TX, USA) under various vaccine rollout scenarios for November 8, 2020–September 17, 2021. A) COVID-19 deaths averted after January 15, 2021, under combinations of vaccine uptake of 50% (left) or 90% (right); type of protection, either infection blocking (reducing susceptibility) or symptom blocking (reducing severity); rollout dates, either January 15 (circles) or February 15 (triangles); and risk prioritization, either no priority (gray), prioritize all adults >65 years of age (light blue), adults with high-risk underlying conditions (medium blue), or the combination of the two (dark blue), or a 10-phase risk-ordered strategy (green) that sequentially vaccinates >65 y high risk, 50–64 y high risk, >65 y low risk, 18–49 y high risk, 50–64 y low risk, 18–49 y low risk, 0–4 y high risk, 5–17 y high risk, 0–4 y low risk, 5–17 y low risk. Points and whiskers indicate the median and 95% CI across 200 paired stochastic simulations. B) Weekly incident COVID-19 deaths per 100,000 population, assuming intermediate (70%) uptake (6) without vaccine (black) or under a 10-phase risk-based rollout of a 95% efficacious infection-blocking vaccine, starting either January 15 (orange) or February 15 (purple). The brown line assumes that only first doses are administered starting January 15. Solid lines and shading indicate the median and 95% CI across 200 stochastic simulations. COVID-19, coronavirus disease.

Similar articles

Cited by

References

    1. Vaccines and Related Biological Products Advisory Committee. FDA briefing document: Moderna COVID-19 vaccine. December 17, 2020. [cited 2021 May 7]. https://www.fda.gov/media/144434/download
    1. Vaccines and Related Biological Products Advisory Committee. FDA briefing document: Pfizer BioNTech COVID-19 vaccine. December 10, 2020. [cited 2021 May 7]. https://www.fda.gov/media/144245/download
    1. US Food and Drug Administration. COVID-19 vaccines. [cited 2021 Feb 17]. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-dise...
    1. Dooling K, McClung N, Chamberland M, Marin M, Wallace M, Bell BP, et al. The Advisory Committee on Immunization Practices’ interim recommendation for allocating initial supplies of COVID-19 vaccine—United States, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1857–9. 10.15585/mmwr.mm6949e1 - DOI - PMC - PubMed
    1. US Centers for Disease Control and Prevention. Vaccines for COVID-19. 2021. [cited 2021 Feb 15]. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html

Publication types

Substances